News-1024x255.jpg
 

March 19 - 22, 2018

Cristcot will attend DCAT 2018   

 

June 9, 2017

Cristcot Receives European Patent

 

May 30, 2017

Cristcot Receives US Patent

 

April 27, 2017

Cristcot Receives European Patent

 

May 2016

Cristcot Repays MLSC Loan

 

Cristcot will attend the international pharmaceutical conference, DCAT (Drug, Chemical and Applied Technologies), in New York City.  The DCAT conference brings together innovator and generic drug companies with ingredient suppliers, manufacturers, packagers and service providers.  We welcome the opportunity to meet you in New York at DCAT.  To schedule a meeting, please contact us at info@cristcot.com.

 

The European Patent Convention has granted Patent No. 2344231 to Cristcot for the invention of a Method and Apparatus for Inserting a Rectal Suppository.  This patent extends the Company's intellectual property portfolio beyond the US and further protects the technology of Sephure.

 

The European Patent Convention has granted Patent No. 2908793 to Cristcot for the invention of a Suppository Insertion Device, Suppository, and Method of Manufacturing a Suppository.  All of the claims within the patent application were deemed to be novel, include inventive step and are deemed to have commercial usefulness.

 

The United States Patent Office has granted Patent No. 9,662,481 to Cristcot for the invention of a Method and Apparatus for Inserting a Rectal Suppository.  The patent claims cover technology of the Sephure device and are a part of the Company's growing portfolio of intellectual property. 

 

In 2012, Cristcot was awarded an Accelerator Loan from the Massachusetts Life Sciences after a competitive application and selection process.  After exceeding all benchmarks of success for the MLSC Accelerator Loan program, Cristcot repaid the loan early, including principle and interest, with revenue generated from sales of the Sephure device.